Product: Fasoracetam
CAS: 110958-19-5
MF: C10H16N2O2
MW: 196.248
Storage Temp.: Store at RT
Appearance: White Solid
Usage: Nootropics
1. Fasoracetam is a research compound and member of the racetam family of nootropics,primarily known for their cognitive enhancing abilities. Fasoracetam is also an anxiolytic and may be able to improve mood as well. This racetam works by affecting three receptors within the brain: acetylcholine,GABA and glutamate, all of three of which are involved in the creation and retention of memories.
2. It is now a nootropic smart drug which portrays itself in one of the most powerful racetams in the nootropic universe. Made from a class of compounds called the racetams, and acting on not only acetylcholine but also GABA receptors in the brain, this has the ability of activating both cholinergic and glutamate receptors of the cerebral cortex, and is a revolutionary racetam drug due to its extremely unique mechanism of action. Fasoracetam currently also shows benefits as an anti-depressant, ADHD stimulant, and an anxiolytic, it also, as proven in laboratories across the nation, helps with the formation and retention of new memories.
| Nootropic |
| Sunifiram |
314728-85-3 |
Coluracetam |
135463-81-9 |
| Fasoracetam |
110958-19-5 |
Noopept |
157115-85-0 |
| PRL-8-53 |
51352-87-5 |
Beta nicotinamide mononucleotide |
1094-61-7 |
| Nicotinamide ribose |
1341-23-7 |
Aniracetam |
72432-10-1 |
| Oxiracetam |
62613-82-5 |
Pramiracetam |
68497-62-1 |
| Nebracetam |
116041-13-5 |
Nefiracetam |
77191-36-7 |
| Phenylpiracetam |
77472-70-9 |
Piracetam hydrazide |
59776-89-5 |
| NSI-189 |
1270138-40-3 |
NSI-189 phosphate |
1270138-41-4 |
| Alpha-GPC |
28319-77-9 |
Citicoline |
987-78-0 |
| Citicoline Sodium |
33818-15-4 |
4-Aminobutyric acid |
56-12-2 |
| Phenibut |
1078-21-3 |
Sulbutiamine |
3286-46-2 |
| Unifiram |
272786-64-8 |
Amfonelic acid |
15180-02-6 |
| ANALYTICAL ITEMS |
SPECIFICATION |
ANALYTICAL RESULTS |
| Appearance |
White Solid |
Confirms |
| Related substances |
A single impurity≤0.5% |
0.06% |
| Total impurities≤1.0% |
0.19% |
| Loss on drying |
≤0.5% |
0.09% |
| Assay |
>99.0% |
99.6% |
| Conclusion |
Confirms to Enterprise Standard |
Like many of the nootropics, this member of the racetam family has been studied in controlled settings and there does appear to be a distinct benefit to patients of diseases and conditions that affect the brain and memory. Fasoracetam has proven to show benefit for people suffering from conditions like schizophrenia (Froestl, Muhs and Pfeifer 793). However, there are other studies that show that the greatest benefit of Fasoracetam can be seen in patients with Alzheimer's Disease, helping to reduce the expected loss of mental acuity and memory. Presently, there are more studies being done to determine if Fasoracetam may be a beneficial treatment for some of the young patients who are affected by the varying degree from Attention Deficit Disorder or Attention Deficit Hyperactivity Disorder, or as they are more commonly known, ADD and ADHD.
Specification:
| ANALYTICAL ITEMS |
SPECIFICATION |
ANALYTICAL RESULTS |
| Appearance |
White Solid |
Confirms |
| Related substances |
A single impurity≤0.5% |
0.06% |
| Total impurities≤1.0% |
0.19% |
| Loss on drying |
≤0.5% |
0.09% |
| Assay |
>99.0% |
99.6% |
| Conclusion |
Confirms to Enterprise Standard |
Customers Reviews
Audited Supplier 
){kind=link}